Join
Live feed
·
PRReleasevia Quantisnow
Immatics N.V. logo

Immatics Achieves Clinical Proof-of-Concept of its Next-Generation TCR Bispecific (TCER®) Pipeline with Data on IMA402 (PRAME) and IMA401 (MAGEA4/8) and Announces Next Development Steps

ByQuantisnow·Wall Street's wire, on your screen.
IMTX· Immatics N.V.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track IMTX (Immatics N.V.) and more on Quantisnow.